To assess the potency of anti-CD38-IFNα(att) compared to standard MM therapeutics, we tested anti-CD38-IFNα(att) along with several registered compounds in the NCI-H929 xenograft model. The gene discussed is IFNA2; the disease is Miyoshi myopathy.